- Home
- TARA vs ALEC Comparison
TARA vs ALEC Comparison
Compare TARA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | ALEC |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.5M | 133.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TARA | ALEC |
|---|---|---|
| Price | $5.12 | $1.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $20.40 | $3.33 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 11-10-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $69,048,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $155.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $2.77 | $0.87 |
| 52 Week High | $7.82 | $3.40 |
Technical Indicators
Market Signals| Indicator | TARA | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 65.23 |
| Support Level | $5.18 | $1.50 |
| Resistance Level | $5.80 | $1.62 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 3.90 | 98.55 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.